FROM DATA TO DISCOVERY: THE ART OF DXA ANALYSIS IN RESEARCH

>>> This amazing webinar is now over!
If you want to learn about IAG’s capabilities in DXA, or watch the recording, click here!

If you’re planning a clinical study or developing a new treatment focusing on bone health, osteoporosis, obesity, and related conditions, perhaps you should consider incorporating DXA!

DXA – Dual-Energy X-ray Absorptiometry or DEXA – is a valuable tool in clinical trials. Its importance lies in its ability to accurately measure bone mineral density and body composition, providing quantitative data that can be crucial for assessing the efficacy of interventions and treatments.

Join our panel of experts to discuss the significance of DXA, exploring practical use cases and uncover how IAG excels in effectively managing its clinical trials.

Presenter: Michael Clark
A Senior Clinical Director with extensive experience in undertaking strategic planning, oversight and execution of clinical programs and leading staff across multiple project areas globally. Skilled in needs assessment, quality assurance, managing programmes, communicating deadlines and completing projects within budget and on-time. Committed to achieving and exceeding targets in a drive to meet business objectives with strong clinical expertise and stakeholder management abilities.

Presenter: Prof. Mikael Boesen
Prof. Boesen, IAG’s Therapeutic Area Lead for Rheumatic Diseases and Auto-Immunity, is a professor of radiology with focus on musculoskeletal imaging and development of novel therapeutics for rheumatic and autoimmune conditions. He heads musculoskeletal imaging and research groups at Copenhagen University and Bispebjerg and Frederiksberg Hospital in the Capital region of Denmark. He has 20 years hands-on international experience in clinical research in inflammatory and degenerative joint diseases and serves as a global PI and expert reader on trials. He is an author of 200+ articles, chapters and abstracts and he has served as supervisor of more than 30 PhD students and postdocs. He brings together cross-therapeutic area expertise into musculoskeletal imaging from previous work in immuno-oncology and cardiac imaging and he currently spearheads implementation of artificial intelligence into radiological image analysis in EU and the USA, all of which he uses to help drug development companies to think outside the box when it comes to designing clinical trials and selecting appropriate imaging strategy.

Presenter: Cristiano Costa
With over a decade of experience in cross-sectional diagnostic imaging and a background in healthcare management Cristiano brings a blend of clinical expertise and administrative skills to the healthcare industry. This multifaceted experience contributes to the enhancement of healthcare delivery and the optimization of clinical workflows, enabling streamlined and efficient processes.

Moderator: Julia O’Lynn
With 20+ years of expertise in targeted drug development and advanced radiologic imaging, Julia advises life science companies on how to accelerate drug development and commercialization.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  ia-grp.com

Reach out: contact@ia-grp.com

Follow the Company: Linkedin

AI and Precision Medicine in Solid Tumors

AI and Precision Medicine in Solid Tumors

In this live discussion, IAG’s imaging experts will share their experience in delivering central review in oncology clinical trials, reader performance monitoring, and factors leading to site central discordance. Our experts will cover different radiographic response assessment criteria, such as RECIST 1.1, irRECIST, Choi etc.

Join our live discussion with experts on how to incorporate an efficient imaging strategy and volumetrics and radiomics into drug development programs.

​​​​​​​Key discussion points:

• Imaging endpoints in oncology and regulatory requirements
• Site vs central reading: benefits, challengers, and opportunities
• Assessment criteria in solid tumors: choosing the right criteria
• Volumetrics and radiomics in solid tumors

Presenter: Dr. Anitha Singareddy:
Dr. Singareddy is a board-certified physician having more than 13 years of experience in clinical research, CRO industry and medical imaging as well as extensive experience in medical imaging in the solid tumour portfolio using RECIST 1.1, iRECIST and other oncology review criteria.

Presenter: Dr. Andrew Patterson:
Dr Patterson has experience in selecting optimal imaging and AI strategies to accelerate drug development. Dr. Patterson is an active researcher with over 70 papers focusing on the development of novel imaging biomarkers.

Moderator: Julia O’Lynn:
With 20+ years of expertise in targeted drug development and advanced radiologic imaging, Julia advises life science companies on how to accelerate drug development and commercialization.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

Taking holistic approach to trial design, regulatory pathway, value creation and investment proposition can vastly increase chances of success for the developers of advanced therapies.

Watch this webinar

“Cell & Gene Therapies: Rethinking Development & Value Creation” – presented by Dr. Sven Kili, IAG’s Member of Scientific Advisory board and Cell & Gene Therapy Senior Leader.

Key discussions points:

• Development of Cell or Gene Therapy
• Optimising clinical development and study design
• Regulatory pathways in the EU and USA
• Value creation and investment proposition

The session will begin with Dr. Kili’s talk and will be followed by a live Q&A to give the audience the opportunity to gain insight into their own development programs.

This webinar is organized by IAG, Image Analysis Group, a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. wp1.ia-grp.com

Dr. Sven Kili is pharmaceutical physician and clinician, who spent his career on supporting pharma and biotech companies in developing and commercialising innovative advanced therapies. In his talk he will share an insight into ethics, drug development and value creation when it comes to development of novel advanced therapies.

Questions? Email: imaging.experts@ia-grp.com

Many Bio-Pharma partnerships are currently focused on the development of vaccines and cures for patients with lung diseases, including long Covid19. This is the time to be specific and strategic with designing your trials and planning your resources.

IAG team and collaborators recorded this live webinar, designed for the drug developers focused on the lung diseases.

Key discussions points:

• Overview of clinical and imaging features of patients with lung diseases;
• Imaging in the drug trials of Covid19 and lung diseases;
• Imaging biomarkers for drugs in development;
• AI and modern infrastructure in relevance to these drug trials.

The session will begin with a joined talk by Dr. Faiq Shaikh, IAG’s member of scientific advisory board and Dr. Michael Andersen, IAG’s member of Scientific Advisory Board and Chairman of the Danish Lung Radiology Society, followed by a live Q&A with the audience.

About the Webinar:

This webinar is organized by IAG, Image Analysis Group

IAG’s imaging experts are sharing their knowledge on how imaging, AI and modern trial infrastructure can support drug development for lung diseases, specifically for Covid19 and long covid. The webinar will cover the use of X-ray, CT, PET, immunoPET based imaging endpoints and their relevance in supporting understanding of the efficacy and safety novel therapeutic agents.

About Dr. Faiq Shaikh:

Dr. Faiq Shaikh is IAG’s Head of Research & Enterprise. His background is in medical imaging and informatics. He is a physician with deep expertise in the use of molecular imaging, novel tracers and radiomics in clinical studies. Faiq is closely working with the world-class academic centres, biotechnology and pharmaceutical companies bringing predictive analytics and AI-based outcomes measures to drug development and clinical decision making.

About Dr. Michael Brun Andersen:

Dr. Andresen is a IAG’s Scientific Advisory Board and Chairman of the Danish Lung Radiology Society, expert in imaging and AI for lung diseases.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.  IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

Reach out to our imaging experts at imaging.experts@ia-grp.com

Link to access content

About the Webinar:

Bringing a novel glioblastoma multiforme (‘GBM’) therapy to the market requires a robust clinical trial that will assess the effectiveness of the potential treatment. The design and delivery of such trials is a challenge.

Join our live discussion with experts on how to incorporate an efficient imaging strategy and AI into drug development programs.

Key discussion points:

• Modern trial infrastructure
• Power of Artificial Intelligence (AI)
• RANO, mRANO, iRANO: Choosing the right criteria
• Impacting patient outcomes

Presenter: Dr. Sotirios Bisdas:
Head of Neuro-Oncology and Neurology clinical research at IAG, neuroradiologist, Associate Professor at the Institute of Neurology, UCL, London, UK and professor in radiology at the University of Tübingen, Germany. Dr. Bisdas is an expert and a distinguished PI in many international clinical studies, which rely on the use of cutting-edge methodologies and advanced imaging in assessing efficacy of novel treatments for brain tumours and other neurological conditions. He co-authored 130 peer-reviewed publications, 7 book chapters related to advanced MRI in neurological and oncological diseases.

Presenter: Dr. Andrew Patterson:
Dr Patterson has experience in selecting optimal imaging and AI strategies to accelerate drug development. Dr. Patterson is an active researcher with over 70 papers focusing on the development of novel imaging biomarkers.

Moderator: Julia O’Lynn:
With extensive expertise in radiologic cross-sectional imaging, Julia has in-depth expertise in clinical trial design, advising life science companies how to use imaging-based markers to accelerate their drug development and ensure standardized imaging across multi-center trials. Specializing in neuro-oncology, she helps build biotech partnerships exploring how advanced analysis, AI, and precision medicine can determine early efficacy.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

Join us to discuss rapidly progressive osteoarthritis (RPOA) and challenges of designing and executing Osteoarthritis clinical trials.

Link to the content

The design of osteoarthritis (OA) clinical trials investigating novel OA drug therapeutics has always been challenging. In this webinar, we want to discuss a particular challenge of accounting for patients who may develop rapidly progressive osteoarthritis (RPOA). The etymology and epidemiology of RPOA are not yet well characterised. We nowadays know that the dramatic radiologic manifestations of RPOA can lead to diagnostic confusion with other arthropathies, infection, and osteonecrosis.

Design of a successful clinical trial must incorporate an imaging strategy that would allow to exclude patients who are at risk of developing RPOA, as this would have profound implications on the trial outcomes and safety of patients. It is therefore imperative to understand RPOA and how imaging can assist in defining patient eligibility prior to enrolment as well as monitoring patient safety during clinical trials.

Key discussion points:

• Regulatory perspective and future directions in knee OA drug development
• Observational radiographic features that may lead to prompt diagnosis of RPOA
• Design of clinical trials of osteoarthritis and use of imaging in identifying RPOA

Presenter: Prof. Mikael Boesen:
Professor of musculoskeletal imaging, hands-on radiologist with 20 years of international experience in clinical research in inflammatory and degenerative joint diseases. Prof. Boesen is a global PI, speakers and author of 80+ articles and book chapters. He brings together cross-therapeutic area expertise and helps drug developers to think outside the box when it comes to designing clinical trials and selection imaging strategy.

Presenter: Dr. Lee Simon:
Rheumatologist, physician and research scientist with extensive drug development experience. He served as a director of FDA division for of Analgesic, Anti-inflammatory and Ophthalmologic Drug Products and currently advises many biotech and pharmaceutical companies on designing impactful clinical programs. Dr. Simon is a Principal Consultant and member of IAG’s Scientific Advisory Board.

Moderator: Dr. Olga Kubassova:
CEO of IAG, Image Analysis Group, Mathematician and computer scientist with 10+ years expertise in actively managing innovation in life science companies. Scientific interests are in quantitative imaging, development of novel efficacy methodologies, with AI, Machine Learning for fast objective early decisions in clinical trials.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies, leading AI-powered drug development and precision medicine. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

Speed, quality, and cost of drug development depend on the robust clinical trial design, targeted patient selection and optimal efficacy assessments. Imaging is increasingly used in clinical trials to improve success rate and reveal early evidence of treatment impact.

IAG, Image Analysis Group is a leading medical imaging expert company driving the use of quantitative imaging as an early evidence for drug development. We improve speed and reproducibility of radiological reviews with Computer-Aided workflows and bring smart often AI driven methodologies to extract the full spectrum of information from medical images. Thus, giving biotech or pharma companies early powerful efficacy data in clinical trials.

In this webinar, we will present our proprietary cloud-based platform DYNAMIKA and show how it can increase efficiencies of traditional radiological reviews while integrating the best of advanced quantitative image analysis in clinical trials.

We will show how the flow of an imaging part of a clinical trial improves when operational teams can take advantage of automated data de-identification, built-in audit trail and notification system, automated quality control, and seamless workflows for all trial stakeholders.

Our therapeutic experts will show case studies of early drug evidence, trial enrichment and advanced treatment efficacy assessments from phase I-IV trials in oncology, neurology, and rheumatology.

This webinar will be interesting to those who are responsible for clinical trials operations, design of clinical trial protocols, imaging biomarker selection, patient recruitment and overall success of clinical programs.

Date and Time:

Friday, May 21 2021, 12 PM ET / 5 PM BST

Register on Xtalks

For questions or a replay, email imaging.experts@ia-grp.com

What you will learn:

• De-risking clinical trials and accelerating drug development through efficient central imaging data management and centralized review.
• Powering your trial with DYNAMIKA in a global multi-centre trial setting and delivering complex imaging trials.
• AI-powered controls over your image data quality and radiological reviews.
• Insight into the advanced data analytics / advanced quantitative approaches and their impact on the efficacy data.

Speakers:

Dr. Olga Kubassova, CEO of IAG and life science innovator, mathematician with expertise in actively managing innovation in life science companies, asset positioning, and strategy. Extensive expertise and domain knowledge in identifying innovative approaches to clinical research, disruptive technology platforms and novel therapeutics. Olga is an active researcher, with over 80 publications, books and book chapters. She is a scientific adviser to the UK government and EU funding bodies. Her ambition is to bring truly disruptive technologies, artificial intelligence and best of machine learning to clinical practice and research, while expanding IAG’s footprint and partnerships.

Prof. Jamshid Dehmeshki, CTO of IAG, is a software engineer with passion for medical imaging and 20+ years of mixed academic and commercial background. He is supporting IAG’s bio-pharma clients in the design and delivery of complex imaging trials that require the best in breed technology solutions. Jamshid’s experience is in enterprise development environments, medical device quality control, algorithm development and patenting novel approaches to medical image analysis. He is widely published academic and recognized speaker in the field of medical image analysis, data mining, algorithm development, medical image and video processing, mathematical, stochastic and forecasting modelling and numerical analysis. He has published more than 170 scientific research papers, five book chapters, and holds thirteen patents.

Prof. Mikael Boesen, MD, PhD, Head of Musculoskeletal Research at IAG, professor of radiology with focus on musculoskeletal imaging and head of the musculoskeletal imaging and research at Copenhagen University and Bispebjerg and Frederiksberg Hospital in the Capital region of Denmark. He has 20 years hands-on international experience in clinical research in inflammatory and degenerative joint diseases and serves as a global PI on trials. He is an author of 130+ articles, 6 book chapters and 160 abstracts and he has served as supervisor of more than 20 PhD students and postdocs. He brings together cross-therapeutic area expertise into musculoskeletal imaging from previous work in immuno-oncology and cardiac imaging and he currently spearheads implementation of artificial intelligence into radiological image analysis in Denmark, EU the US all of which he uses to helps drug developers and biotech companies to think outside the box when it comes to designing clinical trials and selecting appropriate imaging strategy within many therapeutic areas.

Prof. Sotirios Bisdas, MD, PhD Head of Neuro-Oncology and Neurology at IAG, neuroradiologist, Senior Lecturer at the Institute of Neurology, UCL, London, UK and professor in radiology at the University of Tübingen, Germany. He is an expert and a distinguished PI in many international clinical studies, which rely on the use of cutting-edge methodologies and advanced imaging in assessing efficacy of novel treatments for brain tumours and other neurological conditions. He co-authored 130 peer-reviewed publications, 7 book chapters related to advanced MRI in neurological and oncological diseases. He is actively involved in designing and publishing guidelines for the use of perfusion imaging in Oncology.

We picked 3 hot topics and invited 3 outstanding speakers to join a live webinar focused on the drug development in Rheumatoid Arthritis (RA):

–    Unmet needs in RA drug development: do we still need new therapies?
–    Trial design: is clinical score enough?
–    Earlier decisions in RA drug development: how imaging and technology can support your clinical programs?

If you are interested in a replay, please reach out to imaging.experts@ia-grp.com

Click here to watch

About the Webinar

While the rheumatoid arthritis drug pipeline is robust with over 240 molecules under study, many will drop off through natural attrition. It has been shown that only 40% of patients are ACR70 responders, which indicates a need for more effective treatment options.

The drug development process is complex, with greater focus being put on personalization of therapeutic strategies, both in the choice of molecules and their place in a patient treatment pathway.

This webinar will be a live discussion on several hot topics.

The moderator and the speakers will start with discussing the need for new therapies and what new therapies mean for the market.

The second topic will be focused on trial design, remission as an outcome, patient inclusion, trial enrichment and patient phenotyping.

The third topic is the use of imaging biomarkers and technology to achieve earlier decisions on treatment efficacy and practical aspects of RA clinical trials.

Dr. Lee Simon, MD
is a rheumatologist, physician and research scientist with extensive drug development experience. He served as a director of FDA division for of Analgesic, Anti-inflammatory and Ophthalmologic Drug Products and currently advises many biotech and pharma companies on designing impactful clinical programs. Dr. Simon is Principal Consultant and member of IAG’s Scientific Advisory Board.

Prof. Mikael Boesen, MD, PhD
is a professor of musculoskeletal imaging and hands-on radiologist with 20 years of international experience in clinical research in inflammatory and degenerative joint diseases. Dr. Boesen is a global PI, speaker, and author of 130+ articles and book chapters. He brings together cross-therapeutic area expertise and helps drug developers to think outside the box when it comes to designing clinical trials and selection imaging strategy. Prof. Boesen is IAG’s Lead for Musculoskeletal Clinical Research.

Prof. Philip Conaghan, MB, BS, Phd, FRACP, FRCP

is an academic rheumatologist and Director of the arthritis research Institute at the University of Leeds, UK. He has major research interests in understanding pathogenesis and improving the therapies for common arthritides, especially osteoarthritis, rheumatoid and psoriatic arthritis, with a focus on outcome measurement, modern imaging modalities, and optimising patient phenotypes for clinical trials and practice.

Moderator: Dr. Olga Kubassova
is CEO of IAG, Image Analysis Group, mathematician and computer scientist with 10+ years expertise in actively managing innovation in life science companies. Scientific interests are in quantitative imaging and development of novel efficacy methodologies, with AI, Machine Learning for fast objective early decisions in clinical trials.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.  IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin

Today’s oncology R&D programs require precision in early go / no go decisions and clarity on the treatment impact. Despite the FDA’s guidance on the imaging endpoint process, research shows that variability of site reads vs central reads is typically between 5-30%.

At IAG, we developed and implemented in over 400 trials a modern trial infrastructure for centralized data collection and central imaging review.

In this live webinar, IAG’s imaging experts will share their experience in delivering central review in oncology clinical trials, with enterprise level platform DYNAMIKA that provides efficiencies, compliance, and security in data management. We will show how such a set-up allows to reduce variability in the reads, both radiology assessments and quantitative image review criteria.

We will discuss added efficiencies and cost savings enabled by DYNAMIKA. Our experts will cover advantages of quantitative imaging alongside standard radiographic response criteria, such as RECIST 1.1, iRECIST, RANO, and Lugano.

If you are interested in a replay, please reach out to imaging.experts@ia-grp.com

Watch this webinar

Key Discussion Points:

• Importance of centralized image interpretation
• Quantitative image analysis and radiological assessments:  the need of centralized imaging interpretations
• Choosing the right imaging strategy and platform for your clinical trial.

Followed by a Q&A.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.  IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin